FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic...
fda.gov